CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Sorafenib Plus Capecitabine (SorCape)drug
Likely dose
Sorafenib Plus Capecitabine (SorCape) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01471353
NCT01471353Phase 2Completed
CompareCT.gov

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

University of Florida·interventional·Posted Nov 16, 2011·Updated Jul 23, 2020

In Brief

A Phase 2 clinical trial evaluating Sorafenib Plus Capecitabine (SorCape) for Colorectal Cancer Metastatic. Completed, enrolled 43 participants across 1 site.

Detailed Summary

Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer Metastatic
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 16, 2011
Enrollment StartNov 1, 2011
Primary CompletionOct 1, 2015
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.6 years ago

Interventions

Sorafenib Plus Capecitabine (SorCape)drug

Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days